Amsacrine
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Amsacrine: From Acute Leukemia to Hyperthyroidism
One-Sentence Summary
Amsacrine (m-AMSA) is a cytotoxic antineoplastic agent established in the treatment of acute leukemia, acting via DNA intercalation and Topoisomerase II inhibition. The TxGNN model predicts it may be effective for Hyperthyroidism, however this association is currently supported by no clinical trials and no published literature. The high TxGNN score (99.37%) most likely reflects indirect knowledge-graph network connectivity rather than a genuine pharmacological relationship, and this prediction should be interpreted with significant caution.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Antineoplastic agent (acute leukemia); not registered in Taiwan |
| Predicted New Indication | Hyperthyroidism |
| TxGNN Prediction Score | 99.37% |
| Evidence Level | L5 |
| Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the current evidence package. Based on available scientific context, Amsacrine (m-AMSA) is a DNA-intercalating cytotoxic agent and Topoisomerase II inhibitor used in oncology — most notably for refractory acute non-lymphocytic leukaemia. Its mechanism involves insertion into the DNA double helix and stabilisation of the Topoisomerase II–DNA cleavage complex, generating DNA double-strand breaks that preferentially destroy rapidly proliferating cells. Cardiotoxicity is a documented class concern noted in the literature.
Hyperthyroidism is characterised by excessive synthesis and secretion of thyroid hormones (T3/T4), most commonly caused by Graves' disease, toxic nodular goitre, or thyroiditis. Standard treatment targets thyroid hormone synthesis (thionamides), radioiodine uptake, or peripheral adrenergic effects (beta-blockers). No established biological pathway connects Topoisomerase II inhibition or DNA intercalation to thyroid hormone regulation or thyroid gland physiology.
The repurposing rationale analysis explicitly identifies this prediction as a probable false positive: the TxGNN high score likely arises from indirect node linkages in the disease knowledge graph — such as shared comorbidity or immune-modulation nodes — rather than a real pharmacological interaction between Amsacrine and hyperthyroidism pathophysiology. This prediction does not meet the threshold for mechanistic plausibility required to advance beyond a model-prediction-only stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (DNA intercalating agent / Topoisomerase II inhibitor) |
| Myelosuppression Risk | High — cytotoxic mechanism targeting rapidly dividing cells; haematological toxicity expected based on drug class |
| Emetogenicity Classification | Moderate |
| Monitoring Items | CBC with differential, ECG and cardiac function monitoring (known cardiotoxicity — confirmed in in vitro comparative studies with heart myocytes), liver and renal function |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no mechanistic basis connecting Amsacrine's Topoisomerase II inhibition and DNA intercalation to hyperthyroidism pathophysiology, no registered clinical trials, and no published literature supporting this indication. The TxGNN rank-1 prediction is assessed as a likely knowledge-graph false positive driven by indirect disease-node connectivity.
To proceed, the following is needed:
- Formal mechanism of action data (MOA) from DrugBank to enable structured mechanistic analysis
- Identification of a biologically plausible pathway linking Topoisomerase II inhibition to thyroid hormone synthesis or secretion (none currently known)
- At minimum one hypothesis-generating in vitro or in silico study before any clinical consideration can be entertained
Alternative candidate warranting priority review: The rank-2 TxGNN prediction — Plasma Cell Myeloma (score 99.32%, Evidence Level L3) — is mechanistically more plausible (Topoisomerase II inhibition against a highly proliferative plasma cell tumour) and is supported by 7 published studies including two Phase II single-arm trials (PMID 6688199 and 2913481). Although both trials showed insufficient single-agent efficacy, the existing evidence base makes Plasma Cell Myeloma a more productive target for repurposing evaluation — particularly in combination regimens or specific patient subgroups.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.